Sanofi announced on April 26 it will fill and finish up to 200 million doses of Moderna’s COVID-19 vaccine, starting in September at its site in Ridgefield.

“Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity across the industry,” said Paul Hudson, chief executive officer for Bridgewater-based Sanofi.

“We are one of the few pharmaceutical companies to leverage many industrial partnerships to improve global supply and access to COVID-19 vaccines, while in parallel, also continuing to develop our two COVID-19 vaccine programs,” Hudson continued. “I would also like to acknowledge the contributions of the Department of Health and Human Services, and the Biden administration, to facilitate this new partnership.”

This marks Sanofi’s third commitment to provide manufacturing support. It is the only large manufacturer to support all three vaccine efforts.

Earlier this year, Sanofi announced it would provide support to BioNTech for 125 million vaccine doses for the European Union. In February, Sanofi announced one of its manufacturing sites in France would support Johnson & Johnson for the production of its COVID-19 vaccine at a rate of approximately 12 million doses per month.

Separately, Sanofi said it is continuing continues to prioritize development of its two COVID-19 vaccine candidates

Sanofi is collaborating with GSK on a COVID-19 vaccine candidate using the same recombinant protein-based manufacturing technology as one of Sanofi’s seasonal influenza vaccines, combined with GSK’s established pandemic adjuvant platform.

On Feb. 22, Sanofi and GSK announced the beginning of a new Phase 2 study with an improved antigen formulation. Enrollment of 720 total  participants was completed on March 8 and results are expected in the second quarter of 2021. This vaccine is anticipated to be available in Q4 2021, pending Phase 3 outcomes and regulatory authorizations.

In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio. In March 2021, Sanofi and Translate Bio initiated a Phase 1/2 clinical trial of their mRNA COVID-19 vaccine candidate to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels.